Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00331747|
Recruitment Status : Unknown
Verified July 2006 by Sheba Medical Center.
Recruitment status was: Recruiting
First Posted : May 31, 2006
Last Update Posted : July 7, 2006
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients.
During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Drug: Glatiramer acetate||Not Applicable|
Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate. The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1 system, 4 AMTI force plates and a Noraxon telemetric EMG system. Patients will be videotaped and will also undergo a detailed physical examination by a physical therapist.
Treatment with Glatiramer acetate will be initiated after the gait analysis. Therapy will be observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center.
Repeat gait analysis will be performed after one year of treatment.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate|
|Study Start Date :||May 2006|
- Computerized gait analysis: at the beginning of treatment and after 1 year
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331747
|Contact: Uri Givon, MDemail@example.com|
|Multiple Sclerosis Center, Sheba Medical Center||Recruiting|
|Tel Hashomer, Israel, 52621|
|Principal Investigator: Uri Givon, MD|
|Principal Investigator:||Uri Givon, MD||Sheba Medical Center; Tel Aviv University|
|Study Chair:||Anat Achiron, MD, PhD||Sheba Medical Center; Tel Aviv University|